Clinical trial data suggest that BV retreatment may be an option following a response (typically >6 months) to an initial BV regimen in cHL (ORR, 53–60%; CR rate, 18–30%) [6,7,8] and CD30-expressing PTCLs (ORR, 59–88%; CR rate, 38–67%) [3,6,7,8]. The gene discussed is TNFRSF8; the disease is classic Hodgkin lymphoma.